Abstract

The occurrence of nosocomial infections has been on the rise for the past twenty years. Notably, infections caused by the Gram-positive bacteria Staphylococcus aureus represent a major clinical problem, as an increase in antibiotic multi-resistant strains has accompanied this rise. There is thus a crucial need to find and characterize new antibiotics against Gram-positive bacteria, and against antibiotic-resistant strains in general. We identified a new dermaseptin, DMS-DA6, produced by the skin of the Mexican frog Pachymedusa dacnicolor, with specific antibacterial activity against Gram-positive bacteria. This peptide is particularly effective against two multiple drug-resistant strains Enterococcus faecium BM4147 and Staphylococcus aureus DAR5829, and has no hemolytic activity. DMS-DA6 is naturally produced with the C-terminal carboxyl group in either the free or amide forms. By using Gram-positive model membranes and different experimental approaches, we showed that both forms of the peptide adopt an α-helical fold and have the same ability to insert into, and to disorganize a membrane composed of anionic lipids. However, the bactericidal capacity of DMS-DA6-NH2 was consistently more potent than that of DMS-DA6-OH. Remarkably, rather than resulting from the interaction with the negatively charged lipids of the membrane, or from a more stable conformation towards proteolysis, the increased capacity to permeabilize the membrane of Gram-positive bacteria of the carboxyamidated form of DMS-DA6 was found to result from its enhanced ability to interact with peptidoglycan.

Highlights

  • The World Health Organization (WHO) recently reported that infectious diseases account for nearly 13% of global deaths

  • Fraction I was further separated by reverse phase highperformance liquid chromatography (RP-HPLC) and RP-HPLC fractions were tested for antibacterial activity

  • They were active against the multidrug-resistant strains Enterococcus faecium BM4147 and Staphycoloccus aureus DAR 5829

Read more

Summary

Introduction

The World Health Organization (WHO) recently reported that infectious diseases account for nearly 13% of global deaths. By 2050, the continuous rise in antimicrobial resistance could lead to the death of 10 million people every year [1], notably due to an increase in hospitalrelated infections. According to the WHO, Gram-positive bacteria are involved in major nosocomial infections, with 16% of these infections due to Staphylococcus aureus, one of the twelve families of bacteria considered a major threat for human health Almost 38% of S. aureus strains are resistant to methicillin, and the number of Staphylococcus strains exhibiting resistance to vancomycin, one of the strongest available antibiotics, is increasing. Over a period of twenty years (1995–2017), the number of antibacterial drugs approved by the United States Food and Drug Administration (FDA) has steadily decreased, and only twenty drugs have been approved for sale between 2008 and 2018 (https:// www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infectionsand-infectious-diseases). The worldwide relentless emergence of antibiotic resistance continues to spur the search for novel anti-infectives to replace and/or supplement conventional antibiotics

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call